• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment.

作者信息

Tsai C-C, Chen J-H, Wang Y-C, Chang F-Y

机构信息

Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

Division of Hematology/Oncology, Department of Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.

出版信息

QJM. 2019 Jan 1;112(1):41-42. doi: 10.1093/qjmed/hcy243.

DOI:10.1093/qjmed/hcy243
PMID:30351391
Abstract
摘要

相似文献

1
Re-activation of pulmonary tuberculosis during anti-programmed death-1 (PD-1) treatment.抗程序性死亡蛋白1（PD-1）治疗期间肺结核的再激活
QJM. 2019 Jan 1;112(1):41-42. doi: 10.1093/qjmed/hcy243.
2
Development of pulmonary tuberculosis following treatment with anti-PD-1 for non-small cell lung cancer.非小细胞肺癌抗PD-1治疗后发生的肺结核
Acta Oncol. 2018 Aug;57(8):1127-1128. doi: 10.1080/0284186X.2018.1433877. Epub 2018 Jan 31.
3
Anti-PD-1 Drug (Nivolumab) May Induce Acute and Life-Threatening Pancreatitis in Lung Cancer Patient: A Case Report.抗程序性死亡蛋白1（PD-1）药物（纳武单抗）可能诱发肺癌患者发生急性且危及生命的胰腺炎：一例报告
Pancreas. 2018 Sep;47(8):e53-e54. doi: 10.1097/MPA.0000000000001107.
4
Complete response upon salvage chemotherapy after anti-PD1 failure: Watch and wait.抗PD-1治疗失败后挽救性化疗获得完全缓解：观察与等待。
Eur J Cancer. 2021 Mar;145:155-157. doi: 10.1016/j.ejca.2020.12.020. Epub 2021 Jan 18.
5
Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.一名接受纳武单抗治疗的宫颈鳞状细胞癌患者出现自发消退的爆发性角化棘皮瘤。
J Dermatol. 2019 May;46(5):e177-e178. doi: 10.1111/1346-8138.14684. Epub 2018 Oct 24.
6
γδ T cell clonal proliferation early after PD-1 blockade.PD-1阻断后早期γδT细胞克隆性增殖。
Ann Hematol. 2019 Jan;98(1):219-220. doi: 10.1007/s00277-018-3406-6. Epub 2018 Jun 26.
7
[Anti-PD1 immunotherapy followed by tuberculosis infection or reactivation].抗程序性死亡蛋白1免疫疗法继发结核感染或再激活
Rev Mal Respir. 2020 Sep;37(7):595-601. doi: 10.1016/j.rmr.2020.06.003. Epub 2020 Jul 4.
8
Spontaneous hematoma of the thigh associated with antiproteinase-3 antibody in a patient with metastatic squamous cell carcinoma treated with nivolumab.一名接受纳武单抗治疗的转移性鳞状细胞癌患者出现与抗蛋白酶-3抗体相关的大腿自发性血肿。
J Oncol Pharm Pract. 2019 Jul;25(5):1261-1264. doi: 10.1177/1078155218786352. Epub 2018 Jul 9.
9
Paradoxical response in a patient with non-small cell lung cancer who received nivolumab followed by anti-Mycobacterium tuberculosis agents.一名接受纳武单抗治疗后再使用抗结核分枝杆菌药物的非小细胞肺癌患者出现的矛盾反应。
J Infect Chemother. 2019 Jan;25(1):54-58. doi: 10.1016/j.jiac.2018.06.016. Epub 2018 Jul 25.
10
Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma.一名接受抗程序性死亡-1（PD-1）抑制剂治疗复发霍奇金淋巴瘤的患者发生了肺结核复发。
Acta Oncol. 2016;55(4):519-20. doi: 10.3109/0284186X.2015.1125017. Epub 2016 Jan 12.

引用本文的文献

1
The monogenic landscape of human infectious diseases.人类传染病的单基因格局。
J Allergy Clin Immunol. 2025 Mar;155(3):768-783. doi: 10.1016/j.jaci.2024.12.1078. Epub 2024 Dec 24.
2
Fever of unknown origin associated with immune checkpoint inhibitors.与免疫检查点抑制剂相关的不明原因发热。
Front Immunol. 2024 Mar 12;15:1364128. doi: 10.3389/fimmu.2024.1364128. eCollection 2024.
3
A narrative review of the controversy on the risk of mycobacterial infections with immune checkpoint inhibitor use: does Goldilocks have the answer?
关于使用免疫检查点抑制剂引发分枝杆菌感染风险争议的叙述性综述：金发姑娘知道答案吗？
J Thorac Dis. 2024 Feb 29;16(2):1601-1624. doi: 10.21037/jtd-23-1395. Epub 2024 Feb 27.
4
Pulmonary Tuberculosis Following Immune Checkpoint Inhibitor Treatment for Recurrent Maxillary Squamous Cell Carcinoma.免疫检查点抑制剂治疗复发性上颌鳞状细胞癌后发生的肺结核
Cureus. 2024 Jan 29;16(1):e53203. doi: 10.7759/cureus.53203. eCollection 2024 Jan.
5
Shift in Tissue-Specific Immune Niches and CD137 Expression in Tuberculoma of Pembrolizumab-Treated Nasopharyngeal Carcinoma Patients.帕博利珠单抗治疗的鼻咽癌患者结核瘤中组织特异性免疫微环境的改变及CD137表达
Cancers (Basel). 2024 Jan 8;16(2):268. doi: 10.3390/cancers16020268.
6
Tuberculosis infection following immune checkpoint inhibitor treatment for advanced cancer: a case report and literature review.免疫检查点抑制剂治疗晚期癌症后的结核感染：病例报告及文献复习。
Front Immunol. 2023 May 25;14:1162190. doi: 10.3389/fimmu.2023.1162190. eCollection 2023.
7
Increased Tuberculosis Incidence Due to Immunotherapy Based on PD-1 and PD-L1 Blockade: A Systematic Review and Meta-Analysis.免疫治疗药物阻断 PD-1/PD-L1 通路导致的结核病发病率增加：一项系统评价和荟萃分析。
Front Immunol. 2022 May 19;13:727220. doi: 10.3389/fimmu.2022.727220. eCollection 2022.
8
Nivolumab Combined With Ipilimumab Treatment Induced Hypophysitis and Immune-Mediated Liver Injury in Advanced Esophageal Squamous Cell Carcinoma: A Case Report.纳武利尤单抗联合伊匹木单抗治疗晚期食管鳞状细胞癌致垂体炎和免疫介导的肝损伤：一例报告
Front Oncol. 2022 Apr 1;12:801924. doi: 10.3389/fonc.2022.801924. eCollection 2022.
9
Tuberculosis reactivation at ileum following immune checkpoint inhibition with pembrolizumab for metastatic nasopharyngeal carcinoma: a case report.免疫检查点抑制剂 pembrolizumab 治疗转移性鼻咽癌后引起回肠结核再激活：一例报告。
BMC Infect Dis. 2021 Nov 10;21(1):1148. doi: 10.1186/s12879-021-06845-7.
10
The dark side of immunotherapy.免疫疗法的阴暗面。
Ann Transl Med. 2021 Jun;9(12):1041. doi: 10.21037/atm-20-4750.